IgA nephropathy
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Renal biopsy confirmed IgAN patients; 2. Aged 18-72 years, gender is not limited; 3. After the maximum tolerated dose of RAS blocker (addition of other antihypertensive drugs when not ineffective), the urine protein (most recently examined) after treatment is between 1.0g and 3.5g/day; 4. eGFR (last inspection): 30 - 120ml/min·1.73m2 (inclusive).
Exclusion criteria
Exclusion criteria: 1. Indications for the use of intensive glucocorticoids for immunosuppressive therapy, such as: nephrotic syndrome with minimal pathology and IgAN, and a proportion of crescents confirmed by renal biopsy within 12 months >50%; 2. Contraindications for immunosuppressive therapy using glucocorticoids, including infections, tuberculosis, malignant tumors, pregnant and lactating patients, etc.; 3. Received immunosuppressive therapy in the past 1 year; 4. Malignant or uncontrolled hypertension (systolic blood pressure > 160mm or diastolic blood pressure > 110mmHg); 5. Have clear secondary causes, such as autoimmune diseases, cirrhosis and other secondary IgA nephropathy; 6. Poor compliance, not with treatment; 7. Participate in other clinical studies (involved or participated in the previous month).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of eGFR>40%, renal replacement therapy, ESRD; | — |
Secondary
| Measure | Time frame |
|---|---|
| Glomerular filtration rate;Urinary protein creatinine ratio;24h urine protein quantitation;Blood uric acid; | — |
Countries
China
Contacts
Nephrology Department, Hangzhou Hospital of Traditional Chinese Medicine, Zhejiang